Autologous immune-cell therapy practiced in Japan, helping Vinmec Hospital after technology transfer
16/10/2022
Technology transfer on cell therapy to Vietnam by GN Corporation leads to new opportunities
Press release
Webiner on “Cell Therapy Approaches for Urethral Stricture” jointly held with Edogawa Hospital
1/10/2022
Webiner on Cell Therapy Approaches for Urethral Stricture is held on 16 OCt 2022
Paper on Potential of Beta-Glucan Products to Prevent and Treat Non-Alcoholic Fatty Liver Disease
1/10/2022
A look at the potential of beta-glucan for the growing number of non-alcoholic fatty liver diseases
Tackling long COVID-19, with safety proven Japanese Beta Glucans; The first clinical report in the world
8/10/2021
Paper on potential of beta glucan products is pubrished
Path-breaking feat of reversing in-vitro aging of human chondrocytes; published in Nature Journal
10/7/2021
The paper is published in Scientific Reports, Nature Journal
New Advances in Regenerative Treatments for Cartilage Injuries Published in THE KNEE
11/3/2021
GNC succeeded in culturing hyaluronic acid-rich chondrocytes in a 3D tissue engineering platform.
News
“neu REFIX ” potentials in Duchenne Muscular Dystrophy will be presented at MENA Rare Diseases Conference in UAE
19/4/2024
“neu REFIX ” potentials in Duchenne Muscular Dystrophy will be
“Nichi Glucan” and “Nichi BRITE” potentials will be presented at an academic conference in Osaka, Japan
19/4/2024
“Nichi Glucan” and “Nichi BRITE” potentials will be presented at
Discovery of a safe adjuvant to Duchenne Muscular Dystrophy – A journey of 14 years of passion, pursuits & perseverance.
27/11/2023
A curiosity driven sojourn, across disciplines in science, led to